HC Wainwright Estimates Liquidia FY2030 Earnings

Liquidia Corporation (NASDAQ:LQDA) – Investment analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Liquidia in a report released on Monday, March 2nd. HC Wainwright analyst A. Fein anticipates that the company will earn $9.85 per share for the year. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share.

Several other brokerages have also recently commented on LQDA. Zacks Research cut shares of Liquidia from a “strong-buy” rating to a “hold” rating in a report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. BTIG Research reaffirmed a “buy” rating and issued a $49.00 target price on shares of Liquidia in a research report on Friday, January 9th. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.67.

Liquidia Price Performance

Shares of LQDA opened at $34.52 on Wednesday. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia has a twelve month low of $11.26 and a twelve month high of $46.67. The stock has a market capitalization of $3.00 billion, a P/E ratio of -23.97, a P/E/G ratio of 0.60 and a beta of 0.52. The company has a 50 day moving average of $37.07 and a 200-day moving average of $30.84.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $92.02 million during the quarter. The company’s revenue for the quarter was up 3072.4% on a year-over-year basis.

Insider Buying and Selling

In other Liquidia news, CAO Dana Boyle sold 1,580 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $41.65, for a total value of $65,807.00. Following the sale, the chief accounting officer owned 178,848 shares in the company, valued at $7,449,019.20. This represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Russell Schundler sold 27,289 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,021,427.27. Following the completion of the sale, the general counsel directly owned 579,394 shares of the company’s stock, valued at approximately $21,686,717.42. The trade was a 4.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 212,534 shares of company stock worth $7,964,719 in the last 90 days. 26.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Farallon Capital Management LLC lifted its stake in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares during the last quarter. TCG Crossover Management LLC bought a new position in Liquidia in the 3rd quarter valued at about $38,887,000. Caprock Group LLC acquired a new stake in Liquidia during the third quarter worth approximately $37,114,000. Tyro Capital Management LLC acquired a new stake in Liquidia during the second quarter worth approximately $15,473,000. Finally, MPM Bioimpact LLC boosted its holdings in shares of Liquidia by 600.4% during the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after acquiring an additional 1,200,869 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Strong commercial traction for YUTREPIA — Liquidia reported YUTREPIA net product sales of $148.3M for full‑year 2025 and $90.1M in Q4, with >3,600 unique prescriptions and ~2,900 patients started since launch; management highlighted high prescription‑to‑start conversion and expanding prescriber adoption. This supports revenue growth expectations and de‑risking of the commercial story. GlobeNewswire Release
• Positive Sentiment: Improving profitability and balance sheet — the company reported its second consecutive profitable quarter (Q4 net income $14.6M; adjusted EBITDA $27.3M) and ended 2025 with ~$190.7M cash, giving Liquidia capacity to fund commercialization and development from operations. Quiver Quant / Release
• Positive Sentiment: Earnings context — Q4 EPS was $0.15. That beat the Zacks estimate ($0.08) and came with $92.0M total revenue for the quarter (huge YoY growth), which may calm concerns despite mixed consensus comparisons. Zacks
• Positive Sentiment: Bullish analyst revisions — HC Wainwright materially raised near‑ and long‑term EPS forecasts (including FY2026–FY2029 upside), signaling that some brokers are now modeling strong multi‑year earnings leverage from YUTREPIA and pipeline programs. That can support higher price targets. MarketBeat / HC Wainwright note
• Neutral Sentiment: Valuation debate — coverage pieces are asking whether it’s “too late” to buy after the recent share surge; these articles reflect elevated expectations and may increase short‑term volatility as investors debate whether price already prices in rapid growth. Yahoo: Is It Too Late?
• Negative Sentiment: High SG&A and full‑year loss — selling, general & administrative costs jumped 93% (to $157.2M) as the company built commercial infrastructure; Liquidia still reported a 2025 net loss of $68.9M (improved vs. 2024), so margin expansion depends on continuing strong product uptake. GlobeNewswire Release
• Negative Sentiment: Insider and institutional selling — multiple insiders have sold shares and a manager recently sold ~$5.1M worth of LQDA, while some large institutions trimmed positions; heavy insider/institutional selling can weigh on sentiment despite operational progress. The Motley Fool
• Negative Sentiment: Ongoing litigation risk — the company notes litigation with United Therapeutics that could threaten product availability in some indications; this remains a material binary risk for revenue sustainability. GlobeNewswire Release

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).